Evidence map›Paper›PMID 33527127›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy.

Emmanouil Papasavvas, Livio Azzoni, Brian N Ross, Matthew Fair, Zhe Yuan, Kwasi Gyampoh, Agnieszka Mackiewicz, Amanda C Sciorillo, Amelie Pagliuzza, Steven M Lada and 15 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. HIV Reservoir: How to Measure It?Current HIV/AIDS reports · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Measuring the Haystack's Needles.The Journal of infectious diseases · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Emmanouil PapasavvasWistar Institute, Philadelphia, Pennsylvania, USA.
Livio AzzoniWistar Institute, Philadelphia, Pennsylvania, USA.
Brian N RossWistar Institute, Philadelphia, Pennsylvania, USA.
Matthew FairWistar Institute, Philadelphia, Pennsylvania, USA.
Zhe YuanWistar Institute, Philadelphia, Pennsylvania, USA.
Kwasi GyampohWistar Institute, Philadelphia, Pennsylvania, USA.
Agnieszka MackiewiczWistar Institute, Philadelphia, Pennsylvania, USA.
Amanda C SciorilloWistar Institute, Philadelphia, Pennsylvania, USA.
Amelie PagliuzzaUniversity of Montreal, Montreal, Canada.
Steven M LadaVeterans Affairs San Diego Healthcare System and the University of California, San Diego, California, USA.
Guoxin WuMerck & Co., Inc., Kenilworth, New Jersey, USA.
Shih Lin GohMerck & Co., Inc., Kenilworth, New Jersey, USA.
Carolyn Bahnck-TeetsMerck & Co., Inc., Kenilworth, New Jersey, USA.
Daniel J HolderMerck & Co., Inc., Kenilworth, New Jersey, USA.
Paul D ZuckMerck & Co., Inc., Kenilworth, New Jersey, USA.
Mohammad DamraWistar Institute, Philadelphia, Pennsylvania, USA.
Kenneth M LynnPresbyterian Hospital, University of Pennsylvania hospital, Philadelphia, Pennsylvania, USA.
Pablo TebasDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Karam MounzerJonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, Pennsylvania, USA.
Jay R KostmanJohn Bell Health Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, Pennsylvania, USA.
Mohamed Abdel-MohsenWistar Institute, Philadelphia, Pennsylvania, USA.
Douglas RichmanVeterans Affairs San Diego Healthcare System and the University of California, San Diego, California, USA.
Nicolas ChomontUniversity of Montreal, Montreal, Canada.
Bonnie J HowellMerck & Co., Inc., Kenilworth, New Jersey, USA.
Luis J MontanerWistar Institute, Philadelphia, Pennsylvania, USA.

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
University of Pennsylvania HIV Clinical Trials UnitUM1AI069534 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ian Frank, PABLO TEBAS · 2012 to 2026
$33.0M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Towards Eradication: Reducing Proviral HIV DNA with Interferon-α ImmunotherapyU01AI110434 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J · 2014 to 2017
$7.2M
Sialic Acid Modulation of HIV-associated Chronic InflammagingR01AG062383 · NIA · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED · 2019 to 2023
$3.0M
Exploring Cell-free Glycomic Interactions in HIV-associated Neurological DisordersR21NS106970 · NINDS · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED, NDHLOVU, LISHOMWA C · 2017 to 2018
$507k
Role of Host Glycosylation in the Galectin-9-Mediated Reversal of HIV LatencyR21AI129636 · NIAID · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED · 2017 to 2018
$496k
Host Glycomic Determinants of HIV Persistence in vivoR21AI143385 · NIAID · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED · 2019 to 2020
$491k
NCI NIH HHS P30 CA010815NIAID NIH HHS P30 AI045008NIAID NIH HHS R21 AI129636NIAID NIH HHS R21 AI143385NIAID NIH HHS U01 AI110434NIAID NIH HHS UM1 AI069534NIAID NIH HHS UM1 AI126620NIA NIH HHS R01 AG062383NINDS NIH HHS R21 NS106970
6 · The paper itself

Abstract

Accurate characterization of the human immunodeficiency virus (HIV) reservoir is imperative to develop an effective cure. HIV was measured in antiretroviral therapy-suppressed individuals using the intact proviral DNA assay (IPDA), along with assays for total or integrated HIV DNA, and inducible HIV RNA or p24. Intact provirus correlated with total and integrated HIV.

Indexed as

HIV-1HIV InfectionsCD4-Positive T-LymphocytesDNA, ViralHumansProvirusesVirus LatencyDNA, ViralHIV latencyintegrated HIVIPDAp24TILDA

Identifiers

PMID33527127
PMCPMC7850524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.